Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Allarity Therapeutics Inc (ALLR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: ALLR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -49.93% | Avg. Invested days 18 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.47M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 1 | Beta 0.07 | 52 Weeks Range 0.61 - 6.00 | Updated Date 08/13/2025 |
52 Weeks Range 0.61 - 6.00 | Updated Date 08/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 648.26 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -48.96% | Return on Equity (TTM) -383.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -9363119 | Price to Sales(TTM) - |
Enterprise Value -9363119 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.08 | Shares Outstanding 15079600 | Shares Floating 15079572 |
Shares Outstanding 15079600 | Shares Floating 15079572 | ||
Percent Insiders 2.63 | Percent Institutions 0.73 |
Upturn AI SWOT
Allarity Therapeutics Inc
Company Overview
History and Background
Allarity Therapeutics, Inc. (formerly Oncology Venture) is a precision medicine company founded in 2006. It focuses on developing oncology drugs based on its proprietary DRPu00ae biomarker technology to predict patient response to specific therapies. It has undergone rebranding and strategic shifts over time.
Core Business Areas
- Drug Development: Develops oncology drugs based on the DRPu00ae biomarker platform, aiming for personalized cancer treatment.
- DRPu00ae Biomarker Platform: Provides a proprietary diagnostic tool to identify patients most likely to respond to specific cancer therapies.
Leadership and Structure
The leadership team typically consists of a CEO, CFO, CSO, and a board of directors. Organizational structure is a typical biopharmaceutical company, with research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Stenoparib: A PARP inhibitor in clinical development for ovarian cancer. Market share data is not publicly available as it is not yet approved. Competitors include GSK (Zejula), AstraZeneca/Merck (Lynparza), and Clovis Oncology (Rubraca).
- Dovitinib: A multi-targeted receptor tyrosine kinase (RTK) inhibitor being developed for renal cell carcinoma. Market share data is not yet available due to its development stage. Competitors include approved tyrosine kinase inhibitors like Sutent and Inlyta.
Market Dynamics
Industry Overview
The oncology drug market is large and growing, driven by increasing cancer incidence and advances in treatment. Precision medicine is a key trend, with emphasis on targeted therapies and biomarker-driven patient selection.
Positioning
Allarity Therapeutics aims to differentiate itself with its DRPu00ae biomarker technology, which seeks to improve patient outcomes by identifying likely responders. However, it competes with larger, established pharmaceutical companies.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. Allarity's position within this TAM is dependent on successful clinical trials and regulatory approvals of its pipeline assets. DRP's potential to personalize treatments impacts its TAM.
Upturn SWOT Analysis
Strengths
- Proprietary DRPu00ae biomarker technology
- Focus on personalized cancer treatment
- Pipeline of drug candidates in clinical development
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- Relatively small company size compared to competitors
Opportunities
- Potential to partner with larger pharmaceutical companies
- Expansion of DRPu00ae technology to other cancer types
- Regulatory approval of Stenoparib or Dovitinib
Threats
- Clinical trial failures
- Competition from established oncology drugs
- Regulatory hurdles
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- GSK (GSK)
- AstraZeneca (AZN)
- Merck (MRK)
- Clovis Oncology (Not Public)
Competitive Landscape
Allarity faces intense competition from larger pharmaceutical companies with greater resources and established market presence. Allarity's success hinges on its proprietary biomarker technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been minimal, characterized by clinical development efforts rather than revenue growth.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals. Analyst projections are speculative.
Recent Initiatives: Recent initiatives include advancing Stenoparib and Dovitinib through clinical trials, and continued biomarker development.
Summary
Allarity Therapeutics is a small biotechnology company with promising biomarker technology. However, its limited resources and dependence on clinical trial success pose significant risks. The company needs to either get a product approved or seek an acquisition to succeed. It should focus on its biomarker technology to help it gain a competitive edge against the larger players in the market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Data may be based on estimates and subject to change. Market share data is based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Allarity Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-12-21 | Founder, CEO & Director Mr. Thomas H. Jensen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.allarity.com |
Full time employees 6 | Website https://www.allarity.com | ||
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.